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Background: The effect of dopaminergic therapy on balance in Parkinson’s disease (PD)
remains unclear, including previous studies that excluded the effect of dyskinesias or
other involuntary movements on postural sway. Additionally, medication’s effects may differ
between fallers and non-fallers. In this study, the authors quantify the effect of dopaminer-
gic medication on postural balance (sway) in advanced PD, with and without dyskinesias,
and consider the patient’s history of falls.
Methods: In 24 patients with advanced idiopathic PD, postural balance was measured
using a strain-gage force platform. Before and after taking dopaminergic medication, the
patient’s postural sway was measured at 30-s intervals to determine sway length (SL) and
sway area (SA). Data analysis included the presence of dyskinesias during “ON” medication
condition and history of previous falls.
Results: No significant changes occurred in SL or SA with dopaminergic treatment for
fallers without dyskinesias or non-fallers with dyskinesias. However, after dopaminergic
treatment, SL and SA were 37.8 and 45% lower, respectively, in non-fallers without dyski-
nesias (indicating better balance) and were 87.4 and 162.8% higher, respectively, in fallers
with dyskinesias (indicating poorer balance). In the ON-medication condition, SL and SA
were larger in patients with dyskinesias when compared with patients without dyskinesias;
SL was larger in fallers than non-fallers in both groups with or without dyskinesias.
Conclusion: Dopaminergic medication effects on postural sway could be a predictive factor
for fall risk in PD patients with and without dyskinesias: specifically, decreased sway could
indicate minimal fall risk whereas no change or increased postural sway could indicate a
high risk.
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INTRODUCTION
Factors contributing to balance impairment in Parkinson’s disease
(PD) patients include disturbed postural reflexes, poor control of
voluntary movements, and side effects of certain medications that
include dyskinesias and orthostatic hypotension (1, 2). The effect
of dopaminergic therapy on postural balance remains controver-
sial. Counterintuitively, several studies have found that postural
sway, a marker of balance impairment characterized by motion
of the body’s center of pressure (CoP), is increased by dopamin-
ergic treatment in patients with advanced PD (3, 4). However,
these studies did not account for the effects of dyskinesias or other
involuntary movements on postural sway. Nova et al. concluded
that dopaminergic medications improved subjective measures of
postural stability in PD patients when measured using the Berg
functional balance scale and the motor subscale of the Unified
Parkinson’s Disease Rating Scale (UPDRS-III) (5). Nevertheless,
doubts remain about the reliability of subjective measures of pos-
tural stability, such as the pull test of the UPDRS-III (6). In another
study of patients in the early stages of the disease, Beuter et al.
demonstrated significant improvement in objective measures of
postural sway after acute dopaminergic treatment (7). However,
balance is typically preserved in the first few years of PD and
dyskinesias are uncommon (8).
With effects of dopaminergic medications on postural balance
examined by others, we uniquely quantify the effect of dopamin-
ergic medication on postural balance (sway) in 24 patients with
advanced PD, with and without dyskinesias, and consider the
patient’s history of falls. Given the importance of identifying
predictors of fall risk and objectively assessing the effect of treat-
ment options on postural balance, we examined sway length (SL)
and area in patients with and without dyskinesias, and with and
without a history of falls.
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MATERIALS AND METHODS
Recruited by the University of Cincinnati (UC) Movement Dis-
orders Center, our 24 patients had idiopathic PD [according to
standard criteria (9)] (Table 1). During the recruitment period,
patients with advanced PD and motor fluctuations, some of which
who were being considered as potential candidates for deep brain
stimulation (DBS), were offered participation in this study.
Patients underwent an evaluation in the “practical off” state
(after overnight fast of at least 12 h from dopaminergic medica-
tions) and after dopaminergic treatment. For transition to on-
state, patients were given their usual dose of medications, except
for a few who took a higher dose than usual. Two patients who
take amantadine for dyskinesia as part of their daily medication
regimen were not given amantadine on the day of testing. The
time between taking dopaminergic medications and on-state test-
ing averaged 1 h 50 min. All patients received and gave informed
consent with protocols approved by the UC Institutional Review
Board. Patients did not receive monetary compensation for their
participation.
CLINICAL EVALUATION
The UPDRS-III was used for each medication condition (10). The
axial subscore was derived from UPDRS items 18, 22 (neck rigidity
only), 27, 28, 29, and 30.
OBJECTIVE MEASURE OF BALANCE
Postural balance or sway was measured using a strain-gage type
force plate platform system (Model #OR6-5-1000, Advanced
Mechanical Technology, Inc.) as previously described (11). Para-
meters of static posturography were collected for 30 s before and
after dopaminergic treatment (OFF- and ON-medication con-
ditions, respectively) (11, 12). Patients were instructed to stand
upright, relax their arms at their sides, and look straight ahead
during testing. They wore a safety harness as a precautionary mea-
sure to prevent falls during testing. Four trials were done in each
state.
DATA ANALYSIS
During each test condition, the force platform system provided six
channels of signals, that is, three orthogonal forces (Fx,F y,F z) and
three moments around three orthogonal axes (M x,M y,M z); these
signals were processed off-line with our custom made software
(Posture60 and KineLysis, University of Cincinnati, 2000). The
force platform system was calibrated as previously described (11).
Briefly, the customized software calculates x-y coordinates of the
patient’s CoP during testing (11, 12) and then plots the movement
relative to this center during a trial (stabilogram) that included a
variety of related outcome measures. Most often, two measures are
used: (1) sway area (SA) describing the total area encompassed by
the stabilogram (in the x-y or the horizontal plane) during each
test period; and (2) SL describing the total length of movement
relative to CoP during each test. Subsequently, an increase in SA,
SL, or both implies worse postural stability.
To compare the effect of dyskinesias on postural sway measure-
ments, patients were classified based on the presence or absence
of dyskinesias. During the ON-medication condition, using the
Modified Dyskinesia Scale, we divided the 24 patients based on
the presence or absence of dyskinesia: with dyskinesia (n= 13)
for rating ≥1 or without dyskinesia (n= 11) for rating zero; both
were for a minimum of 9/12 trials. All ratings were performed
by a Movement Disorders neurologist (Fredy J. Revilla or Andrew
P. Duker). The Modified Dyskinesia Scale rates the severity of
whole-body dyskinesias on a scale of 0–4 (where a rating of 4 rep-
resents highest severity of dyskinesia) and has excellent inter- and
intra-rater reliability (13).
Any history of falls was obtained from patient report and
scrutiny of medical records from within 2 years before evalua-
tion. History of falls was treated as a binary variable; patients
with at least one fall were classified as fallers and patients without
falls were classified as non-fallers. Groups, regardless of fall his-
tory or presence of dyskinesias, did not differ significantly in age,
sex, or disease duration. Levodopa equivalent doses (LEDs) were
comparable between the groups (Table 1).
STATISTICAL ANALYSIS
For statistical analysis, SL and SA were transformed to their nat-
ural logarithms to ensure normal distribution. ANOVA (repeated
measures) was used to assess significance. Significant interactions
were followed up with post hoc tests (Tukey’s HSD tests). An alpha
Table 1 | Patient demographics in 24 patients with advanced PD classified with or without dyskinesia and as faller or non-faller.
Demographic No dyskinesia group (n=11) Dyskinesia group (n=13)
Non-fallers (n=7) Fallers (n=4) Non-fallers (n=4) Fallers (n=9)
Sex Five male, two female Three male, one female Four male Five male, four female
FINDING (MEAN±STANDARD ERROR)
Age years 63.9±3.7 62.7±4.2 58.0±2.2 60.9±2.6
Disease duration years 13.4±2.0 8.0±1.8 11.0±0.9 10.2±1.4
Levodopa equivalent dose (mg) 614.3±65.9 565.5±78.2 716.0±171.1 513.4±66.0
UPDRS-III rating OFF 36.0±1.8 40.0±1.6 38.9±5.4 30.3±2.3
ON 17.2±2.8 18.9±5.5 17.5±1.5 15.2±2.0
Axial UPDRS rating OFF 7.1±0.7 8.3±0.6 9.0±0.6 8.1±0.5
ON 4.0±0.8 4.5±1.2 4.3±1.1 3.6±0.4
Postural stability rating OFF 0.7±0.3 0.8±0.5 1.3±0.5 0.7±0.2
ON 0 0.3±0.25 0 0
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level of 0.05 was used for all tests. Statistical analysis was performed
using R version 2.10.1.
RESULTS
In quantifying effects of dopaminergic medication on postural
balance measures of SL and SA, we found no significant differ-
ences among our 24 patients with or without dyskinesias and
with or without a history of falls with respect to clinical mea-
sures (UPDRS-III, axial subscore, and postural stability) in either
medication ON or OFF condition (Table 1). However, clini-
cal measures (UPDRS-III, axial subscore, and postural stability)
improved, regardless of fall history and presence of dyskinesias
during testing in the ON state.
Mean (±SEM) LED from all PD medications for the dyski-
nesia and no dyskinesia groups were 576 (±70) and 597 (±49),
respectively. Nine out of 13 PD patients with dyskinesia and 7
out of 11 PD patients without dyskinesia took dopamine ago-
nist medications. Mean (±SEM) LED from dopamine agonists
for the dyskinesia and no dyskinesia groups were 186 (±55) and
189 (±46), respectively. Hence, the dyskinesia and no dyskine-
sia groups were not significantly different from each other with
respect to medications.
In the ON-medication condition, non-fallers without dyski-
nesias improved in both objective and subjective measures of
balance testing, demonstrating improved postural balance with
acute dopaminergic treatment (Figure 1; Table 1). Specifically, for
ON medication, both SL and SA were larger in patients with dysk-
inesias compared with patients without dyskinesias; SL was larger
in fallers than non-fallers with or without dyskinesias (p< 0.001).
In the OFF medication condition, mean SL did not dif-
fer significantly between groups with or without dyskinesias
(Figure 1). However, SA was lower in fallers with dyskinesias than
in non-fallers with (p= 0.004) or without (p= 0.001) dyskinesias.
No significant changes occurred in SL or SA with dopaminergic
treatment for fallers without dyskinesias or non-fallers with dyski-
nesias. However, in the ON-medication condition, SL and SA were
37.8% (p< 0.001) and 45% (p= 0.02) lower, respectively, in non-
fallers without dyskinesias (indicating better balance) and were
87.4% (p< 0.001) and 162.8% (p< 0.001) higher, respectively, in
fallers with dyskinesias (indicating poorer balance) (Figure 1).
Mean dyskinesia scores (mean± SEM) for fallers and non-
fallers were 1.42± 0.14 and 1.75± 0.23, respectively. None of the
PD patients had a dyskinesia rating of 4. Using ANOVA by treat-
ing dyskinesia scores as factors, dyskinesia scores were found to be
highly significant for SL (p< 0.001) and SA (p< 0.001).
DISCUSSION
In our 24 patients with advanced PD, we found association
between differential effect of dopaminergic medication on pos-
tural balance and fall history. In groups with or without dyskinesia,
we could discriminate fallers from non-fallers based on SL values.
Although SL in the ON-medication state was greater in fallers
than non-fallers (Figure 1), further study is needed to determine
if postural sway measurements can become a tool to identify which
non-faller patient may be at risk for falls. Further research should
investigate the effects of dopaminergic medication; specifically,
does decreased postural sway indicate minimal fall risk and no
FIGURE 1 | Effect of dopaminergic medication on postural sway length
(SL) and area (SA). (A) Sway length decreased significantly in non-fallers
without dyskinesia but increased significantly in fallers with dyskinesia. In
the ON state, SL was significantly greater in fallers than non-fallers without
dyskinesia. (B) Sway area increased significantly in fallers with dyskinesia
and decreased significantly in non-fallers without dyskinesia. In the ON
state, SA was significantly greater in both fallers and non-fallers with
dyskinesia than those without dyskinesia (*p<0.05; **p<0.01;
***p< 0.001).
change or increased postural sway indicate a higher risk. For exam-
ple, the magnitude of SL in the ON-medication state may be useful
to identify which patients are at risk of falls. In the ON-medication
state, non-dyskinetic non-faller PD patients had SL comparable
with that of healthy adults (of comparable age). Poor balance in
PD can be implied given the relatively higher measurements in SL
and area in our study groups in both medication states than that
found in healthy adults ages 60–69 years (SA: 2.2± 1.38 cm2 and
SL: 36.37± 10.11 cm for healthy adults).
Although effects of dopaminergic medications on postural
balance have been examined in other studies (Table 2), our
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Table 2 | Summary of studies exploring the effect of dopaminergic medication on postural balance and shortcomings of each study.
Reference Major finding Study limitation
Rocchi et al. (3) Dopaminergic medication Did not explore relationship between postural
sway, history of falls, and dyskinesiasIncreased root mean square of CoP distance from the center of sway and SA in six
patients with advanced PD
Increased sway more in the mediolateral than in the anterior-posterior direction
Interestingly decreased mean sway velocity
Contin et al. (4) Dopaminergic medication Did not explore relationship between postural
sway, history of falls, and dyskinesiasIncreased SL and SA in 32 patients with early PD and 24 patients with advanced PD
Armond et al. (15) Dyskinesias increased postural sway parameters Included only dyskinetic patients
Severity of dyskinesias correlated with level of postural sway Did not explore relationship between
postural sway and history of falls
Beuter et al. (7) Dopaminergic treatment decreased postural sway in patients with early stages of PD Included only patients with early PD
Did not explore relationship between postural
sway, history of falls, and dyskinesias
Nova et al. (5) Dopaminergic treatment improved postural balance, as evaluated by Berg’s
functional balance scale
Used strictly subjective measures
Did not explore relationship between postural
sway, history of falls, and dyskinesias
Revilla et al. In the absence of dyskinesias, dopaminergic medication Binary faller/non-faller with/without
dyskinesia classificationsDecreased SL and SA in non-fallers
Did not significantly affect SL or SA in fallers
In the presence of dyskinesias, dopaminergic medication
Did not significantly affect SL or SA in non-fallers
Increased SL and SA in fallers
study uniquely analyzed postural sway data of patients based
on dyskinesias and fall history. In the ON-medication condition,
non-fallers without dyskinesias improved in both objective and
subjective measures of balance testing, demonstrating improved
postural balance with acute dopaminergic treatment (Figure 1;
Table 1). However, dopaminergic treatment did not significantly
alter sway parameters for non-fallers with dyskinesias (Figure 1);
this discrepancy is presumably due to the effect of dyskinesias on
CoP. Specifically, any extraneous movement causes a shift in CoP
location. In addition, we found that dyskinesia score had a signif-
icant effect on both SL and SA, meaning that postural sway was
affected by dyskinesia severity. Therefore, the presence of dyskine-
sias in these patients possibly masked improvements in postural
balance that resulted after dopaminergic treatment (14).
POSTURAL SWAY FACTORS AND BALANCE
The observed disconnect between the degree of postural sway
(measured by force platform) and UPDRS-III probably reflects
the fact that this particular measurement of postural reflexes
does not account for the effect of dyskinesias. This interpreta-
tion agrees with the findings of others who suggest that dyski-
nesias may increase the risk of falls (1, 2). The pull test of the
UPDRS-III evaluates patients only in their ability to respond to a
uniaxial perturbation. Patients with dyskinesias demonstrated an
improvement in all aspects of the UPDRS-III, including the pull
test. Although this improvement is presumably indicative of the
patient’s improved ability to respond to a posteriorly directed per-
turbation, it cannot comprehensively predict the patient’s ability
to maintain their center of gravity (CoG) within their base of
support. In a study that described this limitation of the pull test,
Bloem et al. found that the test was not adequately predictive of
falls (16). An alternative interpretation of our findings may be
that CoP measurements are not predictive of postural stability in
PD patients with dyskinesias. Rather CoP measurements assess
balance based on the assumption that they reflect CoG position
(17). Balance control describes the maintenance of the body’s CoG
within its base of support whereas postural instability occurs when
the CoG approaches near proximity of this base (18). However,
CoP measurements are not always indicative of CoG position,
especially during non-static conditions (17). Therefore, the pres-
ence of dyskinesias introduced a dynamic component that may
have influenced the measured CoP. The improvement of subjec-
tive measures observed with dopaminergic treatment, even in the
presence of dyskinesias, could suggest that patients were better
able to maintain their CoG within their base of support.
STUDY LIMITATIONS
Among several limitations, the classification of a patient to be
with or without dyskinesia was based solely on this movement
disorder during testing. A patient who often has dyskinesia with
dopaminergic treatment possibly did not develop dyskinesias dur-
ing testing; the opposite is also true. The potential bias of our
classification as fallers or non-fallers was based on patient’s self-
reporting of falls declared during the clinical visit. Given our
limited sample size of 24 patients and that one patient’s data could
greatly influence results, a larger sample size is needed to further
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determine the effects of dyskinesias, medication, and fall history
on postural balance. Also, because of our limited sample size, we
cannot rule out that differences could exist in comparisons where
we did not find statistically significant differences. With the sole use
of CoP measurements, we could not distinguish between patients
who had normal postural control superimposed with dyskinesias
versus patients who had abnormal postural sway in addition to
dyskinesias (19).
In addition to medication effects, further investigations on how
other treatments (e.g., DBS) might influence postural balance
and how fallers and non-fallers respond are needed. Relationships
between CoG and CoP in PD patients also merit future study.
CONCLUSION
Dopaminergic medication appears to affect postural sway among
patients with advanced PD based on the history of falls and pres-
ence of dyskinesias. Response of postural balance to dopaminergic
medication may be predictive of increased fall risk. Dopaminer-
gic medication reduced postural sway for patients with lower fall
risk but conversely had negligible or detrimental effects on pos-
tural sway for those with a higher fall risk. Owing to our limited
sample size, further study on the effect of dyskinesias on postural
stability and differences in postural sway between fallers and non-
fallers are needed, and may help in determining the optimal doses
of dopaminergic medications that provide the maximal possible
benefit with the least side effects.
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